Precigen PGEN Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

Agios PharmaceuticalsAGIO

——

Merck & Co.MRK

——

Other financials

Income statement

See full

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

See full

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

See full

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation

See full

Market cap$1.91B+213%

Enterprise value$2B+234%

P/S72×—

Profitability

See full

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Returns & leverage

See full

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Precigen's share based compensation arrangement by share based payment award options exercisable number?: Precigen (PGEN) reported share based compensation arrangement by share based payment award options exercisable number of $20.37M in Q1 2026.
How has Precigen's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?: Precigen's share based compensation arrangement by share based payment award options exercisable number increased by 22.5% year-over-year, from $16.63M to $20.37M.